Unmet clinical needs for COVID-19 tests in UK health and social care settings

PLoS One. 2020 Nov 12;15(11):e0242125. doi: 10.1371/journal.pone.0242125. eCollection 2020.

Abstract

There is an urgent requirement to identify which clinical settings are in most need of COVID-19 tests and the priority role(s) for tests in these settings to accelerate the development of tests fit for purpose in health and social care across the UK. This study sought to identify and prioritize unmet clinical needs for COVID-19 tests across different settings within the UK health and social care sector via an online survey of health and social care professionals and policymakers. Four hundred and forty-seven responses were received between 22nd May and 15th June 2020. Hospitals and care homes were recognized as the settings with the greatest unmet clinical need for COVID-19 diagnostics, despite reporting more access to laboratory molecular testing than other settings. Hospital staff identified a need for diagnostic tests for symptomatic workers and patients. In contrast, care home staff expressed an urgency for screening at the front door to protect high-risk residents and limit transmission. The length of time to test result was considered a widespread problem with current testing across all settings. Rapid tests for staff were regarded as an area of need across general practice and dental settings alongside tests to limit antibiotics use.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / statistics & numerical data*
  • Coronavirus Infections / diagnosis*
  • Health Services Needs and Demand*
  • Hospitals
  • Humans
  • Nursing Homes
  • Pandemics
  • Pneumonia, Viral / diagnosis*
  • SARS-CoV-2
  • Surveys and Questionnaires
  • United Kingdom

Grants and funding

This study is part of the CONDOR platform (condor-platform.org), which is funded by the UKRI, Asthma UK and the British Lung Foundation. SG, SGU, AW, DAP and AJA are supported by the National Institute for Health Research (NIHR) Newcastle In Vitro Diagnostics Co-operative (http://www.newcastle.mic.nihr.ac.uk/). MaM is supported by the NIHR London In Vitro Diagnostics Co-operative (https://london.ivd.nihr.ac.uk/). YY is supported by the NIHR NIHR Community Healthcare MedTech and In vitro Diagnostics Co-operative (https://www.community.healthcare.mic.nihr.ac.uk/home_). BS and MM are supported by the NIHR Leeds In Vitro Diagnostics Co-operative (https://www.leedsmic.nihr.ac.uk/). PC, MM and BS are supported by the ‘Antimicrobial Resistance Cross Council Initiative’ (Grant number MR/N029976/1), Funding Partners: The Biotechnology and Biological Sciences Research Council (https://bbsrc.ukri.org/), the Engineering and Physical Sciences Research Council (https://epsrc.ukri.org/), and the Medical Research Council (https://mrc.ukri.org/). This work is also supported by the Medical Research Foundation's National AMR Training Programme (https://www.medicalresearchfoundation.org.uk/projects/national-phd-training-programme-in-antimicrobial-resistance-research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript